https://charts.traderzeitung.de/phases/US30161Q1040
string(1448) "{"isin":"US30161Q1040","name":"Exelixis Inc","stock_id_xnas":7873805,"stock_id_xnys":null,"generated_at":"2026-08-09 09:13:00","days":[{"date":"2026-08-05","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":56.71,"close_at":"2026-08-05 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":54.16,"close_at":"2026-08-05 23:18:00","complete":true,"perf_pct":-4.4966}]},{"date":"2026-08-06","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":52.22,"close_at":"2026-08-06 21:59:00","complete":true,"perf_pct":-3.582},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":52.76,"close_at":"2026-08-06 23:25:00","complete":true,"perf_pct":1.0341}]},{"date":"2026-08-07","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":52.7,"close_at":"2026-08-07 15:19:00","complete":true,"perf_pct":-0.1137},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":54.1,"close_at":"2026-08-07 21:59:00","complete":true,"perf_pct":2.6565},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Exelixis Aktie News & Nachrichten
Das Biotechunternehmen Exelixis (EXEL) hat sich auf Tyrosinkinase-Inhibitoren zur Krebsbehandlung spezialisiert....
Über Exelixis habe ich das letzte Mal nach den starken Q2-Zahlen im Juli berichtet. Die Aktie konnte...
Die Aktie des Biotech-Unternehmen Exelixis befindet sich seit etwa 7 Jahren in einer großen Seitwärtsrange,...
